{
    "nct_id": "NCT03600155",
    "official_title": "A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation",
    "inclusion_criteria": "* Patients with evidence of relapsed or refractory AML or MDS following allogeneic stem cell transplantation\n* Patients must have received preparative regimens to include either busulfan- or melphalan-based regimens\n* Patient must have achieved myeloid engraftment as defined by an absolute neutrophil count >= 500 micro/L on 3 consecutive days\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Total bilirubin =< 2 times upper limit of normal (x ULN) (=< 3 x ULN if considered to be due to Gilbert's syndrome)\n* Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN\n* Serum creatinine =< 2 x ULN or glomerular filtration rate (GFR) >= 50\n* Patients must provide written informed consent\n* The interval from the infusion of stem cells to time of initiation of nivolumab or ipilimumab will be at least 6 weeks (42 days)\n* Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\n* Women of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with known allergy or hypersensitivity to nivolumab or ipilimumab or any of their components\n* Patients with acute GVHD > grade 2 at any time during the post-transplant course\n* Patients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating physician\n* Patients with a known history of any of the following autoimmune diseases are excluded:\n\n  * Patients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis)\n  * Patients with a history of rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis)\n* Patients with solid organ allografts (such as renal transplant) are excluded\n* Ongoing immunosuppressive therapy for the treatment of GVHD. Patients receiving GVHD prophylaxis will be allowed on this study\n* Patients with symptomatic central nervous system (CNS) leukemia at the time of evaluation or patients with poorly controlled CNS leukemia\n* Active and uncontrolled disease/(active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association [NYHA] class III/IV, clinically significant and uncontrolled arrhythmia) as judged by the treating physician\n* Patients with known human immunodeficiency virus seropositivity will be excluded\n* Known to be positive for hepatitis B by surface antigen expression. Known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\n* Patients unwilling or unable to comply with the protocol\n* Pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}